Menu
Search
|

Menu

Close
X

Fibrocell Science Inc FCSC.OQ (NASDAQ Stock Exchange Capital Market)

2.27 USD
+0.00 (+0.00%)
As of 4:00 PM EDT
chart
Previous Close 2.27
Open 2.26
Volume 24,729
3m Avg Volume 65,902
Today’s High 2.35
Today’s Low 2.20
52 Week High 19.60
52 Week Low 2.15
Shares Outstanding (mil) 5.68
Market Capitalization (mil) 12.83
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.547
FY17
-7.166
FY16
-5.222
FY15
-12.167
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.86
Price to Sales (TTM)
vs sector
--
8.16
Price to Book (MRQ)
vs sector
2.07
4.20
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
0.00
17.38
LT Debt to Equity (MRQ)
vs sector
0.00
13.24
Return on Investment (TTM)
vs sector
-88.37
13.13
Return on Equity (TTM)
vs sector
-178.69
15.07

EXECUTIVE LEADERSHIP

Douglas Swirsky
Chairman of the Board, Since 2016
Salary: --
Bonus: --
John Maslowski
President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Since 2017
Salary: $230,577.00
Bonus: $57,000.00
Lisa Embon
Vice President - of Corporate Accounting , Controller, Since 2017
Salary: --
Bonus: --
Sean Buckley
Vice President - Business Development, Corporate Secretary, Since 2018
Salary: --
Bonus: --
Kelvin Moore
Lead Independent Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

405 Eagleview Blvd
EXTON   PA   19341-1117

Phone: +1484.7136000

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

SPONSORED STORIES